Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from BiomX ( (PHGE) ).
On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b study due to resource constraints, which led to the decision to file for insolvency proceedings for its Israeli subsidiary, BiomX Ltd. The company is now evaluating strategic options while maintaining its BX011 program for diabetic foot infections.
The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing innovative treatments for bacterial infections. The company is involved in programs targeting various infections, including diabetic foot infections through its subsidiary Adaptive Phage Therapeutics, Inc.
Average Trading Volume: 70,574
Technical Sentiment Signal: Sell
Current Market Cap: $3.73M
See more insights into PHGE stock on TipRanks’ Stock Analysis page.